WaveBreak
Siddarth Narasimhan is a Scientist with experience in protein biochemistry, in-vitro assay development, high throughput screening, outsourcing & CRO management, cross-platform integration, and mentorship. Siddarth previously worked as a Postdoctoral Researcher at EMBL and Utrecht University, where Siddarth also completed their PhD and Master's degrees in Molecular life sciences and Molecular and Cellular Life Sciences, respectively. Prior to their postdoctoral work, Siddarth had a research internship at the Computational Structural Biology Group at Utrecht University focusing on computational studies on disordered peptides and Protein-Peptide interactions.
This person is not in any offices
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.